EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

EMA authorises Venclyxto (venetoclax) for chronic lymphocytic leukemia and related B-cell leukemias, broadening its approved therapeutic use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Venclyxto (Venetoclax)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 27/05/2026